Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Account Payables (2023 - 2025)

Compass Therapeutics' Change in Account Payables history spans 3 years, with the latest figure at -$1.5 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 217.15% year-over-year to -$1.5 million; the TTM value through Dec 2025 reached -$664000.0, up 63.93%, while the annual FY2025 figure was -$664000.0, 63.93% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$1.5 million at Compass Therapeutics, down from $500000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.8 million in Q4 2023 and bottomed at -$3.2 million in Q1 2024.
  • The 3-year median for Change in Account Payables is $53000.0 (2024), against an average of -$149750.0.
  • The largest YoY upside for Change in Account Payables was 315.52% in 2025 against a maximum downside of 217.15% in 2025.
  • A 3-year view of Change in Account Payables shows it stood at $1.8 million in 2023, then dropped by 27.75% to $1.3 million in 2024, then plummeted by 217.15% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Change in Account Payables are -$1.5 million (Q4 2025), $500000.0 (Q3 2025), and $1.0 million (Q2 2025).